Genflow Biosciences
- Company typePublic
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Genflow Biosciences firmographics
Firmographics- Name
- Genflow Biosciences
- Legal name
- Genflow Biosciences plc
- Website
- https://genflowbio.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Genflow Biosciences industry classification
Industry- Product category
- Gene Therapy / Longevity Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Cell & Gene Therapy for Veterinary Regeneration (HLAMANAD)
Keywords
Where Genflow Biosciences is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Genflow Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Human Gene Therapy (GF-1002): Pre-revenue biotech developing SIRT6 gene therapies targeting age-related diseases including MASH, Werner Syndrome, and sarcopenia. Revenue expected from therapeutic product sales upon regulatory approval.
- Animal Health / Veterinary Gene Therapy: Commercialization of canine SIRT6 gene therapy (GF-1004) for companion animal aging. The company is actively pursuing licensing and co-development discussions with Tier-1 animal health companies. Potential for direct commercialization or licensing deals.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels9 records
Genflow Biosciences product offering
Product offeringCore offering
Genflow Biosciences develops gene therapy candidates that deliver a centenarian variant of the SIRT6 gene via AAV vectors to slow or reverse hallmarks of aging in humans and dogs. Its lead human candidate, GF-1002, targets MASH and other age-related conditions, while GF-1004 is a canine SIRT6 gene therapy evaluated in the SLAB aged-beagle clinical study. The company is pre-revenue and intends to monetize these candidates through licensing and co-development deals with pharmaceutical and animal health partners.
Product overview
Genflow Biosciences is a longevity bioscience company developing gene therapies targeting the aging process through delivery of centenarian SIRT6 gene variants. The company's core product portfolio includes GF-1002 (lead gene therapy for MASH targeting humans), GF-1004 (canine-compatible SIRT6 gene therapy for dog longevity), and the SLAB clinical program evaluating the therapy in aged beagles. The company operates through its SIRT6 mRNA payload platform delivered via lipid nanoparticle (LNP) technology, with clinical programs spanning human MASH treatment, veterinary longevity, muscular diseases (sarcopenia, frailty), and glaucoma. Founded in 2020, the company is headquartered in London with R&D facilities in Belgium and a US office in Cambridge, MA.
Differentiator
Problem solved
Functional benefit
Products and services
- GF-1002 Lead gene therapy candidate delivering a centenarian variant of the SIRT6 gene via AAV for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in human patients with advanced fibrosis. Targeted at pharmaceutical partners for licensing and co-development.
- GF-1004 Proprietary canine-compatible SIRT6 gene therapy for addressing age-related decline, sarcopenia, and longevity in companion dogs. Evaluated in the SLAB clinical study and targeted at Tier-1 animal health partners for licensing or co-development.
- SLAB Clinical Program (Sarcopenia and Longevity in Aged Beagles) Proof-of-concept clinical trial program evaluating SIRT6 centenarian gene therapy in 24 aged beagle dogs to assess safety, biological activity, muscle mass preservation, frailty index reduction, and quality-of-life endpoints. Run with Syngene as contract research organisation.
- SIRT6 mRNA Payload with Acuitas LNP Delivery Technology platform combining Genflow's SIRT6 mRNA payload with Acuitas' proprietary lipid nanoparticle (LNP) delivery system for preclinical evaluation studies supporting future development decisions and partnering arrangements.
Quantifiable outcome
- All treatment groups in the SLAB study demonstrated superior survival compared to control animals, with no adverse events observed across dosing periods.
- +3 more outcomes
Companies that use Genflow Biosciences
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Genflow Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genflow Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- CER GroupecorePartnership with CER Groupe (Centre d'Enseignement et de Recherche sur les Animaux de Laboratoire) established to support pre-IND development activities for the company's gene therapy programs.
- Heureka LabscorePartnership with Heureka Labs established to support pre-IND development activities for the company's gene therapy programs.
- Tier-1 Global Animal Health CompaniescoreGenflow expanded its engagement with Tier-1 global animal health companies by entering additional confidentiality agreements for the ongoing review of data from its canine SIRT6 gene therapy programme. The expansion follows positive preliminary interim results reported in February 2026 and reflects a broadening base of third-party evaluation of the company's data and underlying technology. These interactions are exploratory in nature and support an ongoing evaluation process for potential licensing and co-development.
- Acuitas TherapeuticscoreStrategic technology collaboration with Acuitas Therapeutics, a Vancouver-based leader in lipid nanoparticle (LNP) delivery systems, to integrate Acuitas' proprietary LNP platform with Genflow's SIRT6 mRNA payload for preclinical evaluation studies. The collaboration is fully funded by Acuitas with no cash consideration or dilution to Genflow shareholders, representing independent validation of Genflow's proprietary science. Data generated from preclinical studies will inform future development decisions including delivery optimization and potential partnering arrangements for Genflow's SIRT6 platform targeting age-related diseases.
- SyngenecoreSyngene, an independent contract research organisation, manages the dog's longevity clinical trial for Genflow. The trial is controlled, randomised and includes both aesthetic and biological endpoints, running for one year with six months of treatment followed by six months of assessment.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Genflow Biosciences competitors and assessment
Company assessmentDirect peers
- Unity Biotechnology: Clinical-stage biotech developing senolytic therapeutics for age-related ophthalmologic and musculoskeletal diseases. Comparable aging-disease pipeline orientation and small-cap biotech profile, though Unity's modality is small-molecule rather than gene therapy.
- Rejuvenate Bio: Gene therapy company developing AAV-delivered interventions targeting age-related disease in dogs and other species. Highly comparable to Genflow given shared modality (AAV gene therapy), shared target species (canine), and shared thesis (treating aging biology rather than single diseases).
- Loyal for Dogs: Clinical-stage veterinary pharmaceutical company developing drugs (LOY-001, LOY-002) to extend healthspan and lifespan in dogs. Direct peer given Genflow's GF-1004 canine SIRT6 longevity program and shared focus on the companion-dog longevity market.
- BioAge Labs: Clinical-stage biotech identifying drug targets through analysis of human aging biology and developing therapeutics for age-related metabolic and inflammatory diseases. Direct peer given shared 'aging-as-indication' thesis and pipeline of age-related disease programs.
Emerging players
- Verve Therapeutics: Clinical-stage biotech developing in vivo gene editing therapies for cardiovascular disease, including MASH-relevant metabolic indications. Comparable in vivo genetic medicine approach and cardiometabolic disease focus, with a gene-editing rather than gene-replacement modality.
Broad incumbents
- Sarepta Therapeutics: Commercial-stage leader in AAV-based gene therapies for rare genetic diseases. Comparable modality (AAV gene therapy), regulatory pathway (rare disease), and platform-extension logic, though operating at commercial scale versus Genflow's pre-clinical stage.
- Altos Labs: Well-capitalized private biotech pursuing cellular reprogramming to restore cellular health and reverse disease. Overlapping mission in treating fundamental aging biology, though operating at materially greater scale and with a different core modality.
- CRISPR Therapeutics: Commercial-stage gene editing company with approved therapy and pipeline spanning rare genetic and regenerative medicine indications. Comparable genetic medicine modality and rare-disease pipeline focus, though at far greater scale and with different editing chemistry.
- Calico Life Sciences: Alphabet-backed R&D organization focused on understanding the biology of aging and translating insights into therapeutics. Comparable long-horizon aging biology focus, but operates at significantly larger scale and with broader scope than Genflow.
- Regenxbio: Clinical-stage gene therapy company with proprietary AAV delivery platform and approved/in-development rare-disease programs. Comparable AAV-delivered gene therapy modality and rare-disease regulatory strategy (overlap with Genflow's Werner Syndrome orphan approach).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Genflow Biosciences social profiles
Digital presenceGenflow Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genflow Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Genflow Biosciences funding detail
Funding detailFunding overview
Funding rounds10 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genflow Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genflow Biosciences
What does Genflow Biosciences do?
Genflow Biosciences develops gene therapy candidates that deliver a centenarian variant of the SIRT6 gene via AAV vectors to slow or reverse hallmarks of aging in humans and dogs. Its lead human candidate, GF-1002, targets MASH and other age-related conditions, while GF-1004 is a canine SIRT6 gene therapy evaluated in the SLAB aged-beagle clinical study. The company is pre-revenue and intends to monetize these candidates through licensing and co-development deals with pharmaceutical and animal health partners.
Is Genflow Biosciences a public or private company?
Genflow Biosciences is a public company. It is classified as public and is currently operating.
When was Genflow Biosciences founded?
Genflow Biosciences was founded in 2020. It employs 1 to 10 people.
Where is Genflow Biosciences based?
Genflow Biosciences is headquartered in London, United Kingdom, in the Europe region.
How does Genflow Biosciences make money?
Two revenue lines are on record. Human Gene Therapy (GF-1002) is the primary driver. The others are animal Health / Veterinary Gene Therapy.
Who are Genflow Biosciences's main competitors?
Direct peers on record are Unity Biotechnology, Rejuvenate Bio, Loyal for Dogs and BioAge Labs. Verve Therapeutics is listed as an emerging player. Broad incumbents are Sarepta Therapeutics, Altos Labs, CRISPR Therapeutics, Calico Life Sciences and Regenxbio.
Does Genflow Biosciences have an API?
No public API is recorded for Genflow Biosciences.
What industry is Genflow Biosciences in?
Genflow Biosciences's product category is Gene Therapy / Longevity Therapeutics. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2834.